Dec 08, 2021 7:04am EST Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Dec 02, 2021 7:00am EST Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
Nov 24, 2021 7:00am EST Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Nov 23, 2021 4:01pm EST Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation
Nov 19, 2021 7:00am EST Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
Nov 01, 2021 7:00am EDT Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Oct 21, 2021 7:00am EDT Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
Oct 13, 2021 7:00am EDT Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
